CONTRACEPTION AND NEW GENERATION PROGESTIN ONLY PILLS DURING THE COVID 19 PANDEMIA/REVIEW

Yıl 2021, Cilt: 18 Sayı: 1, 746 - 750, 01.04.2021

Nafiye Yılmaz , Gul Nihal Buyuk

https://doi.org/10.38136/jgon.861698

Cited By: 1

Öz

The Novel Coronavirus disease or COVID 19 started in Wuhan city of China in December 2019 and spread to many countries in a very short period of time. The supply of modern contraceptives was severely affected due to lockdown of various low-and middle-income countries, their manufacture has also come to a standstill because of closure of many pharmaceutical companies. COVID-19 pandemic has not changed the indications and the contraindications for the use of the different hormonal contraceptive methods. The sexual and reproductive health care services are very important for any community even in case of pandemic. Contraception should be seen as an essential component of healthcare and contraceptive counseling should continue to be given during the pandemic. Progestin only pills can be an option in cases where it is not possible to provide an appropriate contraceptive counseling.

Anahtar Kelimeler

covid 19, contraception, pandemic, progestin

COVİD 19 PANDEMİSİNDE KONTRASEPSİYON VE YENİ JENERASYON SADECE PROGESTİN İÇEREN HAPLARIN YERİ/DERLEME

Öz

Yeni Koronavirüs hastalığı veya COVID 19, Aralık 2019'da Çin'in Wuhan kentinde başladı ve çok kısa sürede birçok ülkeye yayılmıştır. Modern kontraseptiflerin tedariki, çeşitli düşük ve orta gelirli ülkelerdeki kısıtlamalar nedeniyle ciddi şekilde etkilenmiş olup, birçok ilaç şirketinin kapanması nedeniyle üretimleri de durma noktasına gelmiştir. COVID-19 salgını, farklı hormonal kontraseptif yöntemlerin kullanımına yönelik endikasyonları ve kontrendikasyonları değiştirmemiştir. Cinsel sağlık ve üreme sağlığı hizmetleri, pandemi durumunda bile her toplum için çok önemlidir. Doğum kontrolü, sağlık hizmetlerinin önemli bir bileşeni olarak görülmeli ve pandemi sırasında da aile planlaması danışmanlığı verilmeye devam edilmelidir. Uygun bir kontraseptif danışmanlığın sağlanmasının mümkün olmadığı durumlarda sadece progestin içeren haplar bir seçenek olabilir.

Anahtar Kelimeler

Covid 19, kontrasepsiyon, pandemi, progestin

Kaynakça

• Bchetnia M, Girard C, Duchaine C, Laprise C. The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status. J Infect Public Health. 2020 Nov;13(11):1601-1610.
• World Health Organization (WHO). Gender and COVID-19; Advocacy Brief. WHO; 2020. Accessed August 25, 2020. https://www.who.int/publications-detail/gender-and-covid-19
• Townsend JW, ten Hoope-Bender P, Sheffield J. In the response to COVID-19, we can’t forget health system commitments to contraception and family planning. Int J Gynaecol Obstet. Published online May 16, 2020.
• Fruzzetti F, Cagnacci A, Primiero F, De Leo V, Bastianelli C, Bruni V, Caruso S, Di Carlo C, Farris M, Grandi G, Grasso A, Guida M, Meriggiola M, Paoletti AM, Cianci A, Nappi C, Volpe A. Contraception during Coronavirus-Covid 19 pandemia. Recommendations of the Board of the Italian Society of Contraception. Eur J Contracept Reprod Health Care. 2020 Jun;25(3):231-232.
• Ramírez I, De la Viuda E, Baquedano L, Coronado P, Llaneza P, Mendoza N, Otero B, Sánchez S, Cancelo MJ, Páramo JA, Cano A. Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: Recommendations from the Spanish Menopause Society, Sociedad Española de Ginecología y Obstetricia and SociedadEspañoladeTrombosisyHemostasia.Maturitas. 2020Jul ;137:5762.
• International Planned Parenthood Federation. COVID-19 pandemic cuts access to sexual and reproductive healthcare for women around the world. News release Published online April 9, 2020 Accessed April 30, 2020 https://www.ippf.org/news/covid-19-pandemic-cuts-access-sexual-and-reproductive-healthcare-women-around-world
• Aly J, Haeger KO, Christy AY, Johnson AM. Contraception access during the COVID-19 pandemic. Contracept Reprod Med. 2020 Oct 8;5:17.
• Bateson DJ, Lohr PA, Norman WV, Moreau C, Gemzell-Danielsson K, Blumenthal PD, Hoggart L, Li HR, Aiken ARA, Black KI. The impact of COVID-19 on contraception and abortion care policy and practice: experiences from selected countries. BMJ Sex Reprod Health. 2020 Oct;46(4):241-243.
• American College of Obstetricians and Gynecologists’ Committee on Obstetric Practice. Committee Opinion No. 670: Immediate Postpartum Long-Acting Reversible Contraception. Obstet Gynecol. 2016 Aug;128(2):e32-7.
• Ferreira-Filho ES, de Melo NR, Sorpreso ICE, Bahamondes L, Simões RDS, Soares-Júnior JM, Baracat EC. Contraception and reproductive planning during the COVID-19 pandemic. Expert Rev Clin Pharmacol. 2020 Jun;13(6):615-622. doi: 10.1080/17512433.2020.1782738. Epub 2020 Jun 22.
• Grimes DA, Lopez LM, O'Brien PA, Raymond EG. Progestin-only pills for contraception. Cochrane Database Syst Rev. 2013 Nov 13;(11):CD007541. doi: 10.1002/14651858.CD007541.pub3.
• World Health Organization Department of Reproductive Health and Research (WHO/RHR), Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs (CCP) Knowledge for Health Project. Family Planning: A Global Handbook for Providers (2018 update). Baltimore and Geneva: 2018.
• Trussell J, Aiken ARA, Micks E, Guthrie KA. Efficacy, safety, and personal considerations. In: Hatcher RA, Nelson AL, Trussell J, Cwiak C, Cason P, Policar MS, Edelman A, Aiken ARA, Marrazzo J, Kowal D, eds. Contraceptive technology. 21st ed. New York, NY: Ayer Company Publishers, Inc., 2018.
• Regidor PA. The clinical relevance of progestogens in hormonal contraception: Present status and future developments. Oncotarget. 2018 Oct 2;9(77):34628-34638. doi: 10.18632/oncotarget.26015.
• Brown EJ, Deshmukh P, Antell K. Contraception Update: Oral Contraception. FP Essent. 2017 Nov;462:11-19.
• Pfitzer A, Lathrop E, Bodenheimer A, RamaRao S, Christofield M, MacDonald P, Arnold B, Bhatnagar N, Mielke E, Mikulich M. Opportunities and Challenges of Delivering Postabortion Care and Postpartum Family Planning During the COVID-19 Pandemic. Glob Health Sci Pract. 2020 Oct 2;8(3):335-343.
• World Health Organization (WHO). Medical Eligibility Criteria for Contraceptive Use. 5th edGeneva: WHO;2015. AccessedMarch26,2020.
• Grandi G, Barra F, Ferrero S, Sileo FG, Bertucci E, Napolitano A, Facchinetti F. Hormonal contraception in women with endometriosis: a systematic review. Eur J Contracept Reprod Health Care. 2019 Feb;24(1):61-70.
• Egarter C. Progestogen-only pills: which progestogen would be ideal. Horm Mol Biol Clin Investig. 2020 Jan 10:/j/hmbci.ahead-of-print/hmbci-2019-0042/hmbci-2019-0042.xml.
• Riley T, Sully E, Ahmed Z, Biddlecom A. Estimates of the potential impact of the COVID-19 pandemic on sexual and reproductive health in low- and middle-income countries. Int Perspect Sex Reprod Health. 2020;46:73–76.
• Kurdoğlu Z. Combined Hormonal Contraceptive Usage in Women With COVID-19. IJWHR2021;9:084-085.
• Gavin L, Moskosky S, Carter M, Curtis K, Glass E, Godfrey E, Marcell A, Mautone-Smith N, Pazol K,Tepper N, Zapata L, Centers for Disease Control and Prevention (CDC). Providing quality family planning services: recommendations of CDC and the U.S. Office of Population Affairs. MMW R Recomm Rep. 2014; 25;63(04): 1-54.